Invent Biotechnologies

Executive Summary

Invent Biotechnologies has established itself as a global leader in protein extraction and cell fractionation, offering innovative spin column-based sample preparation technologies that simplify workflows while preserving sample integrity. Founded in 2010 and headquartered in Eden Prairie, the company serves the diagnostics and proteomics markets. Its proprietary methods enable researchers to obtain high-quality protein samples that accurately reflect natural biological states, addressing a critical bottleneck in life science research. Despite being privately held with limited disclosed financials, the company's reputation and widespread adoption among academic and industrial labs position it for steady growth. The proteomics tools market is expanding due to increased demand for precision medicine and biomarker discovery, providing a favorable tailwind. However, the absence of recent funding rounds or major partnerships suggests a conservative growth trajectory. Overall, Invent Biotechnologies is a well-regarded niche player with potential for incremental innovation.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation spin column kit for single-cell proteomics65% success
• TBDStrategic distribution agreement with a major life science supplier50% success
• Q4 2026Publication of landmark study validating technology in cancer biomarker discovery70% success